DENTSPLY SIRONA Inc. $XRAY Shares Purchased by ARK Investment Management LLC

Key Points

• ARK Investment Management LLC increased its stake in DENTSPLY SIRONA Inc. by 32.5%, owning approximately 0.11% of the company, valued at $3,382,000.
• Several hedge funds also acquired stakes in DENTSPLY SIRONA during the second quarter, contributing to institutional investors holding 95.70% of the company's stock.
• The company declared a quarterly dividend of $0.16 per share, with a yield of 4.9%, despite a negative payout ratio of -13.50%.

ARK Investment Management LLC raised its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 32.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 212,959 shares of the medical instruments supplier's stock after purchasing an additional 52,186 shares during the period. ARK Investment Management LLC owned about 0.11% of DENTSPLY SIRONA worth $3,382,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the stock. Chicago Partners Investment Group LLC acquired a new stake in DENTSPLY SIRONA in the 2nd quarter valued at about $277,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of DENTSPLY SIRONA during the 2nd quarter worth about $725,000. Nordea Investment Management AB raised its position in shares of DENTSPLY SIRONA by 71.0% during the 2nd quarter. Nordea Investment Management AB now owns 428,015 shares of the medical instruments supplier's stock worth $6,853,000 after acquiring an additional 177,750 shares in the last quarter. Allianz Asset Management GmbH raised its position in shares of DENTSPLY SIRONA by 56.3% during the 2nd quarter. Allianz Asset Management GmbH now owns 828,670 shares of the medical instruments supplier's stock worth $13,159,000 after acquiring an additional 298,413 shares in the last quarter. Finally, NorthRock Partners LLC acquired a new stake in shares of DENTSPLY SIRONA during the 2nd quarter worth about $207,000. Institutional investors and hedge funds own 95.70% of the company's stock.

Wall Street Analysts Forecast Growth

XRAY has been the topic of several research analyst reports. Needham & Company LLC reissued a "hold" rating on shares of DENTSPLY SIRONA in a research report on Friday, September 26th. Stifel Nicolaus dropped their price target on DENTSPLY SIRONA from $19.00 to $17.00 and set a "hold" rating on the stock in a research note on Friday, August 8th. Barrington Research dropped their price target on DENTSPLY SIRONA from $21.00 to $18.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. Wells Fargo & Company lowered their target price on DENTSPLY SIRONA from $16.00 to $15.00 and set an "equal weight" rating on the stock in a research note on Friday, August 8th. Finally, Evercore ISI lowered their target price on DENTSPLY SIRONA from $17.00 to $13.00 and set an "in-line" rating on the stock in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $18.00.

DENTSPLY SIRONA Stock Up 0.5%

XRAY opened at $13.03 on Thursday. The business has a 50 day simple moving average of $13.37 and a 200-day simple moving average of $14.50. The stock has a market capitalization of $2.60 billion, a P/E ratio of -2.75, a P/E/G ratio of 0.81 and a beta of 0.96. DENTSPLY SIRONA Inc. has a 12 month low of $11.69 and a 12 month high of $24.86. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.69 and a quick ratio of 1.11.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.02. The firm had revenue of $936.00 million during the quarter, compared to analysts' expectations of $929.67 million. DENTSPLY SIRONA had a positive return on equity of 16.33% and a negative net margin of 25.85%.DENTSPLY SIRONA's revenue was down 4.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.49 earnings per share. DENTSPLY SIRONA has set its FY 2025 guidance at 1.800-2.000 EPS. On average, equities analysts anticipate that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current fiscal year.

DENTSPLY SIRONA Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 10th. Investors of record on Friday, September 26th were issued a dividend of $0.16 per share. The ex-dividend date of this dividend was Friday, September 26th. This represents a $0.64 annualized dividend and a yield of 4.9%. DENTSPLY SIRONA's payout ratio is currently -13.50%.

DENTSPLY SIRONA Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.